SS Innovations International (NASDAQ:SSII), the developer of the SSi Mantra™—the first surgical robotic system to be commercially available in India—reported explosive growth for the fiscal year ended December 31, 2025.
The company’s mission to democratize robotic surgery through cost-effective, high-tech solutions resulted in a 105.7% revenue increase, totaling $42.5 million for the year.
The primary driver of this growth was the rapid adoption of the SSi Mantra system.
Installations rose to 103 units, a 119.1% increase over the previous year, with 40 of those installations occurring in the fourth quarter alone.
This clinical momentum translated into a cumulative 7,885 surgeries performed using the system across various specialties, including cardiac, urology, and gynecology.
Financially, the company demonstrated significant operational scaling.
Gross margins expanded to 46%, up from 34% in 2024, reflecting improved manufacturing efficiencies and a higher proportion of recurring revenue from consumables.
SS Innovations also reported a narrowed full-year net loss of $12.1 million, compared to a $19.2 million loss in the prior year.
To fuel its aggressive international expansion, the company completed a private placement in late 2025, raising approximately $18.6 million.
As of December 31, 2025, SS Innovations held $3.2 million in cash.
This capital is being directed toward securing regulatory approvals in high-value markets, with management expecting a formal FDA 510(k) review for the SSi Mantra by mid-2026.